This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Pivotal Trial Results
Post-Hoc Analysis Results
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
EASI-75 at week 12 and PP-NRS4 as early as week 2 achieved for some patients1-3
CIBINQO is an oral, once-daily treatment option1:
Discontinue therapy if an adequate response is not achieved on 200 mg
Studied in 3582 patients with AD across multiple clinical trials4
Have a product question? Request a call from your product representative
Assisting with access and affordability for patients prescribed CIBINQO
Help eligible, commercially insured patients with access to copay savings*
*Limits, terms, and conditions apply.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.